Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs is compelling because its lead asset SL-325 has shown a best-in-mechanism profile with only a 3.7% ADA rate in 72 healthy participants, durable DR3 blockade, and full receptor occupancy at the lowest 0.1 mg/kg dose, supporting quarterly maintenance dosing and a commercially attractive SC option. The company’s differentiated strategy of targeting the receptor DR3 rather than soluble TL1A is reinforced by positive readthrough from Merck’s HS data and by expansion of RECEPTIVE-CD1 to a three-dose, ~232-patient Phase 2b design on track to initiate in 3Q26. Beyond Crohn’s disease, management is planning a 4Q26 Phase 2 HS trial with topline data in 1H28, while SL-846 adds pipeline depth and optionality.

Shattuck Labs is a development-stage biotechnology company whose valuation depends heavily on SL-325 and related DR3 programs, leaving it exposed to clinical and regulatory setbacks, weak efficacy, immunogenicity, or safety signals that could stop development or limit adoption. The company also faces meaningful execution risk from manufacturing, competitive therapies, and regulatory delays, while its clinical development timelines are long and capital intensive, with no expectation of profitability for several years and a likely need for additional financing on uncertain terms. Even the bullish assumptions embed only a 20% PoS for IBD in the clinical NPV model, underscoring how fragile the investment case remains if trials are inconclusive or funding proves inadequate.